Cargando…

Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection

Clostridioides difficile is the most common cause of infectious antibiotic-associated diarrhea, with disease mediated by two major toxins TcdA and TcdB. In severe cases, systemic disease complications may arise, resulting in fatal disease. Systemic disease in animal models has been described, with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mileto, Steven J., Hutton, Melanie L., Walton, Sarah L., Das, Antariksh, Ioannidis, Lisa J., Ketagoda, Don, Quinn, Kylie M., Denton, Kate M., Hansen, Diana S., Lyras, Dena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450906/
https://www.ncbi.nlm.nih.gov/pubmed/36045589
http://dx.doi.org/10.1080/19490976.2022.2117504
_version_ 1784784630421913600
author Mileto, Steven J.
Hutton, Melanie L.
Walton, Sarah L.
Das, Antariksh
Ioannidis, Lisa J.
Ketagoda, Don
Quinn, Kylie M.
Denton, Kate M.
Hansen, Diana S.
Lyras, Dena
author_facet Mileto, Steven J.
Hutton, Melanie L.
Walton, Sarah L.
Das, Antariksh
Ioannidis, Lisa J.
Ketagoda, Don
Quinn, Kylie M.
Denton, Kate M.
Hansen, Diana S.
Lyras, Dena
author_sort Mileto, Steven J.
collection PubMed
description Clostridioides difficile is the most common cause of infectious antibiotic-associated diarrhea, with disease mediated by two major toxins TcdA and TcdB. In severe cases, systemic disease complications may arise, resulting in fatal disease. Systemic disease in animal models has been described, with thymic damage an observable consequence of severe disease in mice. Using a mouse model of C. difficile infection, we examined this disease phenotype, focussing on the thymus and serum markers of systemic disease. The efficacy of bezlotoxumab, a monoclonal TcdB therapeutic, to prevent toxin mediated systemic disease complications was also examined. C. difficile infection causes toxin-dependent thymic damage and CD4(+)CD8(+) thymocyte depletion in mice. These systemic complications coincide with changes in biochemical markers of liver and kidney function, including increased serum urea and creatinine, and hypoglycemia. Administration of bezlotoxumab during C. difficile infection prevents systemic disease and thymic atrophy, without blocking gut damage, suggesting the leakage of gut contents into circulation may influence systemic disease. As the thymus has such a crucial role in T cell production and immune system development, these findings may have important implications in relapse of C. difficile disease and impaired immunity during C. difficile infection. The prevention of thymic atrophy and reduced systemic response following bezlotoxumab treatment, without altering colonic damage, highlights the importance of systemic disease in C. difficile infection, and provides new insights into the mechanism of action for this therapeutic. Abbreviations: Acute kidney injury (AKI); Alanine Transaminase (ALT); Aspartate Aminotransferase (AST); C. difficile infection (CDI); chronic kidney disease (CKD); combined repetitive oligo-peptides (CROPS); cardiovascular disease (CVD); Double positive (DP); hematoxylin and eosin (H&E); immunohistochemical (IHC); multiple organ dysfunction syndrome (MODS); phosphate buffered saline (PBS); standard error of the mean (SEM); surface layer proteins (SLP); Single positive (SP); wild-type (WT).
format Online
Article
Text
id pubmed-9450906
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-94509062022-09-08 Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection Mileto, Steven J. Hutton, Melanie L. Walton, Sarah L. Das, Antariksh Ioannidis, Lisa J. Ketagoda, Don Quinn, Kylie M. Denton, Kate M. Hansen, Diana S. Lyras, Dena Gut Microbes Research Paper Clostridioides difficile is the most common cause of infectious antibiotic-associated diarrhea, with disease mediated by two major toxins TcdA and TcdB. In severe cases, systemic disease complications may arise, resulting in fatal disease. Systemic disease in animal models has been described, with thymic damage an observable consequence of severe disease in mice. Using a mouse model of C. difficile infection, we examined this disease phenotype, focussing on the thymus and serum markers of systemic disease. The efficacy of bezlotoxumab, a monoclonal TcdB therapeutic, to prevent toxin mediated systemic disease complications was also examined. C. difficile infection causes toxin-dependent thymic damage and CD4(+)CD8(+) thymocyte depletion in mice. These systemic complications coincide with changes in biochemical markers of liver and kidney function, including increased serum urea and creatinine, and hypoglycemia. Administration of bezlotoxumab during C. difficile infection prevents systemic disease and thymic atrophy, without blocking gut damage, suggesting the leakage of gut contents into circulation may influence systemic disease. As the thymus has such a crucial role in T cell production and immune system development, these findings may have important implications in relapse of C. difficile disease and impaired immunity during C. difficile infection. The prevention of thymic atrophy and reduced systemic response following bezlotoxumab treatment, without altering colonic damage, highlights the importance of systemic disease in C. difficile infection, and provides new insights into the mechanism of action for this therapeutic. Abbreviations: Acute kidney injury (AKI); Alanine Transaminase (ALT); Aspartate Aminotransferase (AST); C. difficile infection (CDI); chronic kidney disease (CKD); combined repetitive oligo-peptides (CROPS); cardiovascular disease (CVD); Double positive (DP); hematoxylin and eosin (H&E); immunohistochemical (IHC); multiple organ dysfunction syndrome (MODS); phosphate buffered saline (PBS); standard error of the mean (SEM); surface layer proteins (SLP); Single positive (SP); wild-type (WT). Taylor & Francis 2022-08-31 /pmc/articles/PMC9450906/ /pubmed/36045589 http://dx.doi.org/10.1080/19490976.2022.2117504 Text en © 2022 Crown Copyright. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Mileto, Steven J.
Hutton, Melanie L.
Walton, Sarah L.
Das, Antariksh
Ioannidis, Lisa J.
Ketagoda, Don
Quinn, Kylie M.
Denton, Kate M.
Hansen, Diana S.
Lyras, Dena
Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
title Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
title_full Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
title_fullStr Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
title_full_unstemmed Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
title_short Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
title_sort bezlotoxumab prevents extraintestinal organ damage induced by clostridioides difficile infection
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450906/
https://www.ncbi.nlm.nih.gov/pubmed/36045589
http://dx.doi.org/10.1080/19490976.2022.2117504
work_keys_str_mv AT miletostevenj bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT huttonmelaniel bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT waltonsarahl bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT dasantariksh bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT ioannidislisaj bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT ketagodadon bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT quinnkyliem bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT dentonkatem bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT hansendianas bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection
AT lyrasdena bezlotoxumabpreventsextraintestinalorgandamageinducedbyclostridioidesdifficileinfection